Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Maja Skov Kragsnaes
  • Jens Kjeldsen
  • Hans Christian Horn
  • Heidi Lausten Munk
  • Jens Kristian Pedersen
  • Søren Andreas Just
  • Palle Ahlquist
  • Finn Moeller Pedersen
  • Maarten de Wit
  • Sören Möller
  • Vibeke Andersen
  • Karsten Kristiansen
  • Dorte Kinggaard Holm
  • Hanne Marie Holt
  • Robin Christensen
  • Torkell Ellingsen
View graph of relations

OBJECTIVES: Although causality remains to be established, targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel treatment for inflammatory diseases. In this exploratory, proof-of-concept study, we evaluated the safety and efficacy of FMT in psoriatic arthritis (PsA).

METHODS: In this double-blind, parallel-group, placebo-controlled, superiority trial, we randomly allocated (1:1) adults with active peripheral PsA (≥3 swollen joints) despite ongoing treatment with methotrexate to one gastroscopic-guided FMT or sham transplantation into the duodenum. Safety was monitored throughout the trial. The primary efficacy endpoint was the proportion of participants experiencing treatment failure (ie, needing treatment intensification) through 26 weeks. Key secondary endpoints were change in Health Assessment Questionnaire Disability Index (HAQ-DI) and American College of Rheumatology (ACR20) response at week 26.

RESULTS: Of 97 screened, 31 (32%) underwent randomisation (15 allocated to FMT) and 30 (97%) completed the 26-week clinical evaluation. No serious adverse events were observed. Treatment failure occurred more frequently in the FMT group than in the sham group (9 (60%) vs 3 (19%); risk ratio, 3.20; 95% CI 1.06 to 9.62; p=0.018). Improvement in HAQ-DI differed between groups (0.07 vs 0.30) by 0.23 points (95% CI 0.02 to 0.44; p=0.031) in favour of sham. There was no difference in the proportion of ACR20 responders between groups (7 of 15 (47%) vs 8 of 16 (50%)).

CONCLUSIONS: In this first preliminary, interventional randomised controlled trial of FMT in immune-mediated arthritis, we did not observe any serious adverse events. Overall, FMT appeared to be inferior to sham in treating active peripheral PsA.

TRIAL REGISTRATION NUMBER: NCT03058900.

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Volume80
Issue number9
Pages (from-to)1158-1167
Number of pages10
ISSN0003-4967
DOIs
Publication statusPublished - Sep 2021

    Research areas

  • arthritis, inflammation, psoriatic, therapeutics

ID: 67395679